• Lynch Syndrome
    • Hans F A Vasen†
    • Hans F A Vasen†: Influence Statistics

      Hans F A Vasen†

      Hans F A Vasen†

      Show email address

      Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands | Department of Gastroenterology and Hepatology, Leiden University ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Hans F A Vasen†:Expert Impact

      Concepts for whichHans F A Vasen†has direct influence:Lynch syndrome,Colorectal cancer,Breast cancer,Familial adenomatous polyposis,Ovarian cancer,Mutation carriers,Pancreatic cancer,Cancer risk.

      Hans F A Vasen†:KOL impact

      Concepts related to the work of other authors for whichfor which Hans F A Vasen† has influence:Colorectal cancer,Lynch syndrome,Microsatellite instability,Genetic testing,Mismatch repair,Familial adenomatous polyposis,Germline mutations.

      KOL Resume for Hans F A Vasen†


      Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands


      The Netherlands Foundation for the Detection of Hereditary Tumors, Leiden, the Netherlands. Electronic address:


      Department of Gastroenterology & Hepatology, Leiden University Medical Centre, Leiden, The Netherlands; ; The Netherlands Foundation for the Detection of Hereditary Tumours, Leiden, The Netherlands;,

      The Netherlands Foundation for the Detection of Hereditary Tumours, Leiden, the Netherlands


      Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, the Netherlands.

      Netherlands Foundation for the Detection of Hereditary Tumors, 2333, Leiden, ZA, The Netherlands

      Sanne W. ten Broeke, Heleen M. van der Klift, Carli M.J. Tops, Manon Suerink, Frederik J. Hes, Hans F.A. Vasen, Juul T. Wijnen, and Maartje Nielsen, Leiden University Medical Center, Leiden; Encarna Gomez Garcia, Maastricht University Medical Center, Maastricht; Nicoline Hoogerbrugge, Arjen R. Mensenkamp, and Liesbeth Spruijt, Radboud University Medical Center, Nijmegen; Tom G.W. Letteboer, University Medical Center, Utrecht; Theo A.M. van Os and Egbert J.W. Redeker, Academic Medical Center; Liselotte...


      Department of Dermatology, Radboud University Medical Center, Nijmegen 500 HB, The Netherlands


      Hans Vasen, Isaura Ibrahim, Kristin Robbers, Anneke M. van Mil, Thomas Potjer, Bert A. Bonsing, Wilma Bergman, Martin Wasser, and Hans Morreau, Leiden University Medical Center, Leiden; Wouter H. de Vos tot Nederveen Cappel, Isala Clinics, Zwolle, the Netherlands; Carmen Guillen Ponce, Alfredo Carrato, Julie Earl, Evelina Mocci, Enrique Vazquez-Sequeiros, Alfonso Sanjuanbenito, Maria Muñoz-Beltran, and José Montans, Ramón y Cajal University Hospital, Ramón y Cajal Health Research Institute, Madrid, Spain; Emily P. Slater, Elvira Matthäi, Volker Fendrich, and Detlef K. Bartsch, University Hospital Marburg; Christoph Schicker, Martin Steinkamp, and Jens Figiel, Philipps University Marburg, Marburg; Günter Klöppel, Consultation Centre for Pancreatic and Endocrine Tumors, Technical University Munich; Peter Langer, Klinikum Hanau, Hanau, Germany; and Irene Esposito, Innsbruck University Hospital, Innsbruck, Austria.

      Foundation for the Detection of Hereditary Tumours (STOET), Leiden, The Netherlands.

      Hereditary Cancer Registry, Leiden, The Netherlands


      Simone D. Hennink, Andrea E. van der Meulen-de Jong, Ron Wolterbeek, A. Stijn L.P. Crobach, Roeland A. Veenendaal, Hans Morreau, and Hans F.A. Vasen, Leiden University Medical Center; Wiet F.S.J. Crobach, W. Rogier ten Hove, and Anne M.C. Witte, Diaconessenhuis, Leiden; Marco C.J.M. Becx, St Antonius Hospital, Nieuwegein; Michiel van Haastert and Hugo J. Wolters, Martini Hospital; Jan H. Kleibeuker, University Medical Center Groningen, Groningen; Maarten A.C. Meijssen, Juda Vecht, Wouter H. de Vos tot Nederveen Cappel, and Dik Westerveld, Isala Clinics, Zwolle; Fokko M. Nagengast, Radboud University Medical Center, Nijmegen; Marno C.M. Rijk, Amphia Hospital, Breda; Jan M.J.I. Salemans and Marie-Louise Verhulst, Máxima Medical Center; Arnold Stronkhorst, Catharina Hospital, Eindhoven; Hans A.R.E. Tuynman, Medical Center Alkmaar, Alkmaar; Herman Walinga, Reinier de Graaf Gasthuis, Delft; Olaf K. Weinhardt, Scheper Hospital, Emmen; and Annemieke Cats, National Cancer Institute, Amsterdam, the Netherlands.

      Department of Gastroenterology, Leiden University Medical Centre, Rijnsburgerweg 10, 2333 AA, Leiden, Netherlands


      Netherlands Foundation for the Detection of Hereditary Tumors, Leiden, Netherlands


      Dutch Lynch Syndrome Registry, Netherlands Foundation for the Detection of Hereditary Tumors, Leiden, The Netherlands


      Leiden University Medical Center (LUMC) Department of Gastroenterology and Hepatology Leiden the Netherlands


      The Netherlands Foundation for the Detection of Hereditary Tumors, Leiden, The Netherlands, Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands


      Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands

      From Wageningen University, Wageningen


      Department of Gastroenterology and Hepatology, LUMC, Leiden, The Netherlands


      The Netherlands Foundation for the Detection of Hereditary Tumors, 2333 AA, Leiden, The Netherlands


      Department of Gastroenterology & Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands; The Netherlands Foundation for the Detection of Hereditary Tumours, Leiden, The Netherlands


      Leiden University Medical Centre, Leiden, The Netherlands

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Hans F A Vasen† is among the top experts in the world.
      Concept World rank
      344 relatives #1
      findings previous colonoscopy #1
      cdkn2a p16leiden mutation #1
      colorectal surveillance #1
      185 p16leiden #1
      8q233 disease phenotype #1
      hereditary cancer registries #1
      lynch syndrome surgery #1
      10 adenomas apc #1
      classical fap groups #1
      crc characteristics findings #1
      polyposis registers #1
      survival rate hnpccassociated #1
      stage iii subjects #1
      molecular genetic msianalysis #1
      colorectal adenomas netherlands #1
      survival rates hnpccassociated #1
      tumour spectrum study #1
      arid1a expression arid1a #1
      pcr strategy pms2 #1
      onset early stage #1
      nonlynch syndrome #1
      responders colonoscopy #1
      249 carriers #1
      sequence exchange events #1
      67 brain tumors #1
      identification families #1
      95 snack pattern #1
      lynch syndrome role #1
      67456 months #1
      crc aer #1
      adjuvant 5‐fu treatment #1
      msi analysis #1
      hnpccassociated sporadic #1
      survival mutyh #1
      unexplained familial #1
      underlying gene defect #1
      type fibromatoses #1
      surveillance families #1
      msi tumours diploid #1
      fnaderived material ngs #1
      genetic modifiers melanoma #1
      5fu median followup #1
      50–99 adenomas #1
      underwent colonoscopy detailed #1
      pole germline #1
      sister multiple adenomas #1
      – hnpcc #1
      crn nocrn #1
      mmrproteins #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Hans F A Vasen†

      KOL-Index: 21114

      The AURKA oncogene is associated with abnormal chromosome segregation and aneuploidy and predisposition to cancer. Amplification of AURKA has been detected at higher frequency in tumors from BRCA1 and BRCA2 mutation carriers than in sporadic breast tumors, suggesting that overexpression of AURKA and inactivation of BRCA1 and BRCA2 cooperate during tumor development and progression. The F31I polymorphism in AURKA has been associated with breast cancer risk in the homozygous state in prior ...

      Known for Breast Cancer | Brca2 Mutation | Brca1 Genes | F31i Polymorphism | Aurora Kinases
      KOL-Index: 19234

      The switch/sucrose non-fermentable (SWI/SNF) subunit ARID1A (AT-rich interactive domain 1A gene) has been recently postulated as a novel tumor suppressor of gynecologic cancer and one of the driver genes in endometrial carcinogenesis. However, specific relationships with established molecular alterations in endometrioid endometrial cancer (EEC) are currently unknown. We analyzed the expression of ARID1A in 146 endometrial cancers (130 EECs and 16 non-EECs) in relation to alterations in ...

      Known for Microsatellite Instability | Arid1a Expression | Endometrial Cancer | Lynch Syndrome | Akt Pathway
      KOL-Index: 18773

      BACKGROUND & AIMS: Lynch syndrome is caused by variants in DNA mismatch repair (MMR) genes and associated with an increased risk of colorectal cancer (CRC). In patients with Lynch syndrome, CRCs can develop via different pathways. We studied associations between Lynch syndrome-associated variants in MMR genes and risks of adenoma and CRC and somatic mutations in APC and CTNNB1 in tumors in an international cohort of patients.

      METHODS: We combined clinical and molecular data from 3 ...

      Known for Pathogenic Variants | Lynch Syndrome | Crc Patients | Apc Ctnnb1 | Mlh1 Msh2
      KOL-Index: 18395

      A small fraction of families with familial adenomatous polyposis (FAP) display an attenuated form of FAP (AFAP). We aimed to assess the presence of germline mutations in the MUTYH and adenomatous polyposis coli (APC) genes in AFAP families and to compare the clinical features between the two causative genes. Families with clinical AFAP were selected from the Dutch Polyposis Registry according to the following criteria: (a) at least two patients with 10-99 adenomas diagnosed at age >30 ...

      Known for Germline Mutations | Adenomatous Polyposis | Apc Mutyh | Fap Afap | Attenuated Familial
      KOL-Index: 17945

      BACKGROUND: Germ-line mutations in DNA mismatch-repair genes (MSH2, MLH1, PMS1, PMS2, and MSH6) cause susceptibility to hereditary nonpolyposis colorectal cancer. We assessed the prevalence of MSH2 and MLH1 mutations in families suspected of having hereditary nonpolyposis colorectal cancer and evaluated whether clinical findings can predict the outcome of genetic testing.

      METHODS: We used denaturing gradient gel electrophoresis to identify MSH2 and MLH1 mutations in 184 kindreds with ...

      Known for Colorectal Cancer | Genetic Testing | Mutations Msh2 | Clinical Findings | Members Families
      KOL-Index: 17415

      BACKGROUND: Lynch syndrome is a disorder caused by mismatch repair gene mutations. Mutation carriers have a high risk of developing colorectal cancer. In patients with Lynch syndrome in whom colon cancer has been diagnosed, in general, subtotal colectomy instead of partial colectomy is recommended because of the substantial risk of metachronous colorectal cancer. However, the effect of more extensive surgery on quality of life and functional outcome is unknown.

      OBJECTIVE: The aim of this ...

      Known for Lynch Syndrome | Colon Cancer | Quality Life | Subtotal Colectomy | Functional Outcome
      KOL-Index: 17083

      PURPOSE: Hereditary nonpolyposis colorectal cancer (HNPCC) is an autosomal dominant disease characterized by the clustering of colorectal cancer, endometrial cancer, and various other cancers. The disease is caused by mutations in DNA-mismatch-repair (MMR) genes, most frequently in MLH1, MSH2, and MSH6. The aims of the present study were to compare the risk of developing colorectal, endometrial, and other cancers between families with the various MMR-gene mutations.


      Known for Msh2 Mutation Carriers | Colorectal Cancer | Mlh1 Mutation | Hereditary Nonpolyposis | 1 Muts
      KOL-Index: 17049

      BACKGROUND: Men with germline breast cancer 1, early onset (BRCA1) or breast cancer 2, early onset (BRCA2) gene mutations have a higher risk of developing prostate cancer (PCa) than noncarriers. IMPACT (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls) is an international consortium of 62 centres in 20 countries evaluating the use of targeted PCa screening in men with BRCA1/2 mutations.

      OBJECTIVE: To ...

      Known for Cancer Screening | Brca2 Mutation | Impact Study | Brca1 Genes | Targeted Prostate
      KOL-Index: 16975

      Hereditary nonpolyposis colorectal cancer (HNPCC) is a common autosomal dominant cancer-susceptibility condition characterized by early onset colorectal cancer. Germ-line mutations in one of four DNA mismatch repair (MMR) genes, hMSH2, hMLH1, hPMS1, or hPMS2, are known to cause HNPCC. Although many mutations in these genes have been found in HNPCC kindreds complying with the so-called Amsterdam criteria, little is known about the involvement of these genes in families not satisfying ...

      Known for Amsterdam Criteria | Cancer Families | Hereditary Nonpolyposis | Hnpcc Mutations | 1 Muts
      KOL-Index: 16783

      BACKGROUND: Observational studies report reduced colorectal cancer in regular aspirin consumers. Randomised controlled trials have shown reduced risk of adenomas but none have employed prevention of colorectal cancer as a primary endpoint. The CAPP2 trial aimed to investigate the antineoplastic effects of aspirin and a resistant starch in carriers of Lynch syndrome, the major form of hereditary colorectal cancer; we now report long-term follow-up of participants randomly assigned to ...

      Known for Colorectal Cancer | Controlled Trial | Aspirin Placebo | Capp2 Randomised | Primary Endpoint
      KOL-Index: 16493

      PURPOSE: Immunohistochemistry (IHC) and microsatellite instability (MSI) analysis can be used to identify patients with a possible DNA mismatch repair defect [hereditary nonpolyposis colorectal carcinoma (HNPCC)]. The Bethesda criteria have been proposed to select families for determination of MSI. The aims of this study were to assess the yield of MSI analysis in families suspected for HNPCC, to compare the results of immunohistochemical staining and MSI analysis, and to assess the ...

      Known for Hereditary Nonpolyposis | Pms2 Staining | Microsatellite Instability | Msi Analysis | Colorectal Neoplasms
      KOL-Index: 16128

      BACKGROUND: Germline mutations in MSH6 account for 10%-20% of Lynch syndrome colorectal cancers caused by hereditary DNA mismatch repair gene mutations. Because there have been only a few studies of mutation carriers, their cancer risks are uncertain.

      METHODS: We identified 113 families of MSH6 mutation carriers from five countries that we ascertained through family cancer clinics and population-based cancer registries. Mutation status, sex, age, and histories of cancer, polypectomy, and ...

      Known for Mutation Carriers | Lynch Syndrome | Cancer Risks | 95 Women | Colorectal Neoplasms
      KOL-Index: 15645

      Immunohistochemistry (IHC) of mismatch repair (MMR) proteins in colorectal tumors together with microsatellite analysis (MSI) can be helpful in identifying families eligible for mutation analysis. The aims were to determine sensitivity of IHC for MLH1, MSH2, and MSH6 and MSI analysis in tumors from known MMR gene mutation carriers; and to evaluate the use of tissue microarrays for IHC (IHC-TMA) of colon tumors in its ability to identify potential carriers of MMR gene mutations, and ...

      Known for Mismatch Repair | Colorectal Tumors | Mutation Analysis | Msh2 Msh6 | 1 Muts
      KOL-Index: 15384

      BACKGROUND & AIMS: Hereditary nonpolyposis colorectal carcinoma (HNPCC) is caused by a mutated mismatch repair (MMR) gene. The aim of our study was to determine the cumulative risk of developing cancer in a large series of MSH6 mutation carriers.

      METHODS: Mutation analysis was performed in 20 families with a germline mutation in MSH6. We compared the cancer risks between MSH6 and MLH1/MSH2 mutation carriers. Microsatellite instability (MSI) analysis and immunohistochemistry (IHC) were ...

      Known for Cancer Risk | Hereditary Nonpolyposis | Mutation Msh6 | Colorectal Carcinoma | Msi Analysis
      KOL-Index: 14482

      BACKGROUND & AIMS: Two percent to 4% of all cases of colorectal cancer (CRC) are associated with Lynch syndrome. Dominant clustering of CRC (non-Lynch syndrome) accounts for 1%-3% of the cases. Because carcinogenesis is accelerated in Lynch syndrome, an intensive colonoscopic surveillance program has been recommended since 1995. The aim of the study was to evaluate the effectiveness of this program.

      METHODS: The study included 205 Lynch syndrome families with identified mutations in one ...

      Known for Lynch Syndrome | Surveillance Intervals | Colorectal Cancer | Risk Crc | 1 Muts

      Key People For Lynch Syndrome

      Top KOLs in the world
      Henry T Lynch
      breast cancer lynch syndrome brca2 mutation
      Albert de la Chapelle
      colorectal cancer lynch syndrome papillary thyroid carcinoma
      Jukka‐Pekka Mecklin∥
      colorectal cancer lynch syndrome hereditary nonpolyposis
      Hans F A Vasen†
      lynch syndrome colorectal cancer familial adenomatous polyposis
      Noralane M Lindor
      colorectal cancer lynch syndrome mutation carriers
      Päivi T Peltomäki
      colorectal cancer lynch syndrome hereditary nonpolyposis

      Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands | Department of Gastroenterology and Hepatology, Leiden University Medical Centre, 2333 Leiden, The Netherlands;, hfavasen@stoet.nl | Department

    Download on the App StoreGet it on Google Play

    Copyright © 2023 KOL - Key Opinion Leaders, LLC.

    KOL does not provide medical advice, diagnosis or treatment.